EFFECTS OF ANTICOAGULATION THERAPY WITH VITAMIN K ANTAGONISTS ON HOSPITALIZATIONS AND EMERGENCY ROOM ACCESSES IN GROSSETO (ITALY)

Abstract

Background A lot of drug groups are associated with preventable drug-related admissions. Coumarin derivatives, prescribed for the treatment and prevention of deep vein thrombosis or pulmonary embolism or prevention of systemic embolism or stroke in patients with prosthetic heart valves or atrial fibrillation, are often associated  with bleeding. The aim of our study was to estimate the impact of the anticoagulant therapy in the elderly population (over 65 years old) living in Grosseto province, through the hospitalizations and the visits to emergency room, using only current data flows.

Methods In 2013 we conducted a cross sectional study analyzing the database of all pharmaceutical prescriptions, selecting patients living in Grosseto (Italy), which received at least two prescriptions of coumarin derivatives in 2012.  We analyzed the admissions to hospital and the accesses to the emergency rooms (ER) made by each patient, focusing especially on those related to bleeding. For each access to ER we recorded the date, time of stay, diagnosis and outcome. For each hospitalization the information we recorded were the date of admission and discharge diagnosis.

Results 3684 patients were included in our study. 261 (7.1%) patients visited the emergency room for bleeding; 37 (1%) for intracranial bleeding. The accesses made by men were higher than those made by women. The average time of stay in ER was 349 minutes. The admissions to hospital were 96 (2.6%); 42 (1.1%) were admitted to hospital with a diagnosis of major vascular event. 53 patients (20.3 %), accessed to the ER more than one time. The 11.5% was admitted to the hospital more than one time.  

Conclusions Our study tried to estimate the impact of the anticoagulant therapy in the elderly population, living in Grosseto province, showing an important impact of this therapy on the accesses at ER and on admissions at hospital.

https://doi.org/10.15167/2421-4248/jpmh2018.59.1.722
PDF

References

Organization. WH. The safety of medicines in public health programmes: Pharmacovigilance an essential tool. 2006 [cited 2013 25 June]; Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf

Olsen S, Neale G, Schwab K, Psaila B, Patel T, Chapman EJ, et al. Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place. Quality & safety in health care. 2007;16(1):40-4. Epub 2007/02/16.

Laws MB. Adverse drug reactions as cause of admission to hospital: definition of adverse drug reactions needs to include overdose. BMJ. 2004;329(7463):459-60; author reply 60. Epub 2004/08/24.

Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring. Drug safety. 2013;36(3):147-53. Epub 2013/02/19.

Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. Journal of pharmacology & pharmacotherapeutics. 2013;4(Suppl 1):S73-7. Epub 2013/12/19.

Kalisch LM CG, Roughead RE, Gilbert AL. . The prescribing cascade. . Aust Prescr. 2011;34:162-6. .

Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. British journal of clinical pharmacology. 2007;63(2):136-47. Epub 2006/06/29.

Dormann H, Sonst A, Muller F, Vogler R, Patapovas A, Pfistermeister B, et al. Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). Deutsches Arzteblatt international. 2013;110(13):213-9. Epub 2013/04/19.

Lacoste-Roussillon C, Pouyanne P, Haramburu F, Miremont G, Begaud B. Incidence of serious adverse drug reactions in general practice: a prospective study. Clinical pharmacology and therapeutics. 2001;69(6):458-62. Epub 2001/06/15.

Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Annals of internal medicine. 2007;147(11):755-65. Epub 2007/12/07.

Verhoef TI, Redekop WK, Daly AK, van Schie RM, de Boer A, Maitland-van der Zee AH. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British journal of clinical pharmacology. 2014;77(4):626-41. Epub 2013/08/08.

Snipelisky D, Kusumoto F. Current strategies to minimize the bleeding risk of warfarin. Journal of blood medicine. 2013;4:89-99. Epub 2013/09/11.

DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. American heart journal. 2005;149(4):650-6. Epub 2005/07/02.

Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of internal medicine. 2003;139(11):893-900. Epub 2003/12/04.

Kim MM, Metlay J, Cohen A, Feldman H, Hennessy S, Kimmel S, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiology and drug safety. 2010;19(7):731-6. Epub 2010/06/29.

Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450-8. Epub 2014/08/26.

Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? Journal of thrombosis and thrombolysis. 2013;35(2):295-301. Epub 2012/12/18.

Sameer R. Ghate; Joseph Biskupiak; Xiangyang Ye WJKaDIB. All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation. Journal of Managed Care Pharmacy. 2011;17(9):672-84.

Levorato S, Bocci G, Troiano G, Messina G, Nante N. Health status of homeless persons: a pilot study in the Padua municipal dorm. Annali di igiene : medicina preventiva e di comunita. 2017;29(1):54-62. Epub 2017/01/10.

Messina G, Quercioli C, Troiano G, Russo C, Barbini E, Nistico F, et al. Italian medical students quality of life: years 2005-2015. Annali di igiene : medicina preventiva e di comunita. 2016;28(4):245-51. Epub 2016/08/02.

Nante N, Gialluca L, De Corso M, Troiano G, Verzuri A, Messina G. Quality of life in refugees and asylum seekers in Italy: a pilot study. Annali dell'Istituto superiore di sanita. 2016;52(3):424-7. Epub 2016/10/05.